Feb 18, 2022
Presentation to highlight oral difelikefalin Phase 3 pruritus programs STAMFORD, Conn. , Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
Additional Formats
Jan 10, 2022
Study met both primary and secondary endpoints STAMFORD, Conn. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced
Additional Formats
Displaying 21 - 26 of 26
email alerts